The US peptide status index
Every peptide, filed by what United States law actually permits.
Peptide America is a reference index. For each molecule it records whether an FDA-approved product exists, whether a licensed 503A pharmacy may compound it, or whether no lawful route exists at all — each posture dated, sourced to the primary record, and re-verified when the ground moves. It moved twice in 2026.
Some outbound links are partner links — how this reference is funded. Nothing here is medical advice.
The year the ground moved
62 dated entries across 7 months of 2026, one column per month, counted by how many molecules the record moved. The tallest column is 14.
- 2Mar
- 14Apr
- 10May
- 2Jun
- 7Jul
- 14Aug
- 13Sep
Start with a monograph
- PCAC-recommended · pendingBPC-157
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule.
- FDA-approvedSemaglutide
Approved brand products; mass compounding ended after the shortage resolved; narrow patient-specific 503A path remains.
- Compoundable (503A)Sermorelin
Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A.
- PCAC-recommended · pendingMOTS-c
Removed from Category 2 in April 2026; PCAC recommended 503A listing in July 2026 on a reported tally; no FDA final rule.
Latest evidence reviews
Recent research
- Bremelanotide: Desire and Distress TrialsWhat did bremelanotide improve in the RECONNECT trials?
- Semaglutide Withdrawal: Weight Regain EvidenceHow much weight returns after stopping semaglutide?
- Tirzepatide: Sleep Apnea Trial EvidenceDoes tirzepatide treat sleep apnea or only reduce weight?
- Carnosine: Glucose and Vascular EvidenceWhy do carnosine studies report positive and negative metabolic results?
Every molecule, by what the law allows
The whole index in one view. A posture is a legal position on a date, not a judgment about whether a molecule works.
The July 2026 committee votes
6 of the 7 substances the Pharmacy Compounding Advisory Committee reviewed won a recommendation to be added to the section 503A bulks list. None of them may be compounded today. A recommendation is advisory; only an FDA final rule changes what a pharmacy may do, and none has issued.
- BPC-1578–61 abstention · 15 votingPCAC-recommended · pending
- KPV8–61 abstention · 15 votingPCAC-recommended · pending
- Semax8–51 abstention · 14 votingPCAC-recommended · pending
- TB-5008–61 abstention · 15 votingPCAC-recommended · pending
- Epitalon7–41 abstention · 12 votingPCAC-recommended · pending
- MOTS-c7–52 abstentions · 14 votingPCAC-recommended · pending
- DSIP6–71 abstention · 14 votingNo lawful route
Every tally above is a reported figure, not a primary one: FDA has published no minutes, transcript or vote summary for the meeting. Each is attributed on the molecule’s own page, where two independent accounts are cited and agree. The full vote ledger.
Where a lawful supply exists today
6 of the 15 molecules with a lawful route have a supplier this index has read and dated; 9 are lawful and have none yet. No supplier is listed for any of the 25 without a lawful route; the partner card on each page names no molecule.
Partner programs; this reference earns a commission on starts. How this reference is funded.
Approved brand products; mass compounding ended after the shortage resolved; narrow patient-specific 503A path remains.
Approved brand products; shortage resolved October 2024; same narrow 503A posture as semaglutide.
Previously approved (Geref), discontinued in 2008 for business reasons; compounded today under 503A.
Category 1 of the interim 503A bulks list; compoundable with a valid prescription while FDA evaluates.
Category 1 of the interim 503A bulks list; compoundable with a valid prescription.
Nominations withdrawn April 2026; the non-injectable route was restored to Category 1 in May, the injectable route was not and has no lawful route.
27 suppliers across 6 molecules. Nothing here is a recommendation, no supplier pays for a status, and no supplier is listed for a molecule without a lawful route.
What sits behind the index
Evidence reviews
Each one answers a single question and shows the records it was answered from.
- What did bremelanotide improve in the RECONNECT trials?
- How much weight returns after stopping semaglutide?
- Does tirzepatide treat sleep apnea or only reduce weight?
- Why do carnosine studies report positive and negative metabolic results?
- What does the dulaglutide-versus-semaglutide evidence actually compare?
- Do LL-37 wound studies establish that the peptide works?
Reference tables
The underlying record, assembled once and cited — several of these exist nowhere else.
Filed by class
The same index cut the other way, by what a molecule is rather than what the law says about it.